Cargando…
Real-World Data (RWD) on the 3-Year Follow-Up Outcomes of Different CNS Prophylaxis Strategies Across CNS-IPI Risk Groups in Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma
PURPOSE: CNS relapse in patients with diffuse large B-cell lymphoma (DLBCL) is associated with poor prognosis with a median survival of about 2.5 months. Data demonstrating best prophylactic strategy remain controversial and need further definition. PATIENTS AND METHODS: We present data of 110 patie...
Autores principales: | Faqah, Anadil, Asif, Summaiya, Goksu, Suleyman Yasin, Sheikh, Hassan S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8162514/ https://www.ncbi.nlm.nih.gov/pubmed/33835825 http://dx.doi.org/10.1200/GO.20.00422 |
Ejemplares similares
-
Simplicity at the cost of predictive accuracy in diffuse large B‐cell lymphoma: a critical assessment of the R‐IPI, IPI, and NCCN‐IPI
por: Biccler, Jorne, et al.
Publicado: (2017) -
Interim (18)F-FDG PET/CT improves the prognostic value of S-IPI, R-IPI and NCCN-IPI in patients with diffuse large B-cell lymphoma
por: Jiang, Maoqing, et al.
Publicado: (2017) -
Impact of central nervous system (CNS) prophylaxis on the incidence of CNS relapse in patients with high-risk diffuse large B cell/follicular grade 3B lymphoma
por: Kuitunen, Hanne, et al.
Publicado: (2020) -
Primary CNS Lymphoma
por: Phillips, Elizabeth H., et al.
Publicado: (2014) -
Prophylaxis with intrathecal or high-dose methotrexate in diffuse large B-cell lymphoma and high risk of CNS relapse
por: Bobillo, Sabela, et al.
Publicado: (2021)